C OSBORNE to Risk Assessment
This is a "connection" page, showing publications C OSBORNE has written about Risk Assessment.
Connection Strength
0.039
-
Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women. J Natl Cancer Inst. 2010 Nov 17; 102(22):1706-15.
Score: 0.011
-
Manganese superoxide dismutase polymorphism, treatment-related toxicity and disease-free survival in SWOG 8897 clinical trial for breast cancer. Breast Cancer Res Treat. 2010 Nov; 124(2):433-9.
Score: 0.010
-
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010 Jan; 11(1):55-65.
Score: 0.010
-
Sequenced compared with simultaneous anthracycline and cyclophosphamide in high-risk stage I and II breast cancer: final analysis from INT-0137 (S9313). J Clin Oncol. 2007 Feb 20; 25(6):656-61.
Score: 0.008